Bleeding complications during lepirudin treatment
| Anticoagulation intensity* . | . | Investigation cohort . | Evaluation cohort . | ||
|---|---|---|---|---|---|
| Over (n = 14) . | Target (n = 31) . | Under (n = 8) . | Target (n = 15) . | ||
| Life-threatening bleeding | n | 1 | 0 | 0 | 0 |
| Hb decrease, g/L | Median (IQR) | 11 (9-15) | 10 (3-14) | 10 (6-17) | 10 (3-14) |
| Hb decrease ≥20 g/L | n/N (%) | 3/14 (21.4) | 3/31 (9.7) | 2/8 (25.0) | 1/15 (6.7) |
| Patients requiring PRBC† | n/N (%) | 6/14 (43.6) | 10/31 (32.6) | 1/8 (12.5) | 5/15 (33.3) |
| Patients requiring > 2 PRBCs | n/N (%) | 4/14 (28.6) | 3/31 (9.7) | 1/8 (12.5) | 1/15 (6.7) |
| Units of PRBC/transfused patient | Median | 5 | 2 | 6 | 2 |
| Anticoagulation intensity* . | . | Investigation cohort . | Evaluation cohort . | ||
|---|---|---|---|---|---|
| Over (n = 14) . | Target (n = 31) . | Under (n = 8) . | Target (n = 15) . | ||
| Life-threatening bleeding | n | 1 | 0 | 0 | 0 |
| Hb decrease, g/L | Median (IQR) | 11 (9-15) | 10 (3-14) | 10 (6-17) | 10 (3-14) |
| Hb decrease ≥20 g/L | n/N (%) | 3/14 (21.4) | 3/31 (9.7) | 2/8 (25.0) | 1/15 (6.7) |
| Patients requiring PRBC† | n/N (%) | 6/14 (43.6) | 10/31 (32.6) | 1/8 (12.5) | 5/15 (33.3) |
| Patients requiring > 2 PRBCs | n/N (%) | 4/14 (28.6) | 3/31 (9.7) | 1/8 (12.5) | 1/15 (6.7) |
| Units of PRBC/transfused patient | Median | 5 | 2 | 6 | 2 |